GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Brown-Forman Rejects Sazerac’s $15 Billion Takeover Bid as Family Backs Independence 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
Galp Shares Fall After Q2 EBITDA Miss Despite Profit Beat and Higher Dividend 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance 
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth 
Zhongji Innolight Raises $6.8 Billion in Hong Kong IPO as AI Demand Fuels Growth 
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue 
ASML, Applied Materials Slide as China DUV Chip Equipment Breakthrough Sparks Market Jitters 
CATL Shares Jump as $5.6 Billion Buyback Signals Confidence in Long-Term Growth 
Seagate Stock Jumps as AI-Fueled Earnings Beat and Strong FY2027 Outlook Impress Investors 
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy 
The U.S. Federal Circuit Court of Appeals in Washington, D.C. reinstated a 2017 jury verdict ordering Teva Pharmaceutical Industries Ltd to pay $235.5 million to GlaxoSmithKline Plc for selling a generic version of a heart drug, covered by the latter's patent.
In a 2-1 decision, the appeals court found “substantial evidence” that Teva induced doctors to prescribe its generic tablets.
Israeli drugmaker Teva plans to appeal and introduce additional defenses that it neither infringed nor induced doctors to infringe Glaxo’s patent.
The case arose after Teva began selling a generic version of Coreg, which Glaxo had won U.S. approval for, in 2007.
Coreg treats hypertension, left ventricular dysfunction after a heart attack, and congestive heart failure.
In 2017, a Delaware jury ordered the to pay $234.1 million for lost profit plus $1.4 million in royalties.
US District Judge Leonard Stark overturned the verdict due to other factors that could have caused doctors to prescribe Coreg.
But Circuit Judge Pauline Newman said Teva's promotional materials, product catalogs, the FDA labels, press releases, and witness testimony supported allegations of “induced infringement.”
